GlaxoSmithKline Pharmaceuticals (500660) Status Update summary

Strategic focus, leadership, and portfolio development

• Maintains a diversified healthcare portfolio with renewed focus on respiratory and adult vaccination segments, supported by experienced leadership and a culture of innovation and accountability.

• Digital transformation and omnichannel strategies increased healthcare practitioner touchpoints by 20%, with over 7.6 million digital interactions in Q1.

• Pediatric vaccine business achieved double-digit growth, outperforming the market with a unit Evolution Index of 103.

• Shingrix and adult vaccination ecosystem expanded, with 17% quarter-on-quarter growth and consumer awareness campaigns reaching 55 million people.

• Partnerships with clinics and hospitals expanded disease awareness and vaccination access.

Financial performance and margin improvement

• Q1 FY25 revenue grew 10% to ₹811 crore, with EBITDA up 62% and PAT up 39%, reflecting strong double-digit growth.

• EBITDA margin improved to 28%, up 9 percentage points year-on-year, driven by price optimization, cost containment, and productivity gains.

• Field productivity increased by 31%, and nearly 100% of profits converted to cash, supporting healthy cash flow.

• Vaccine business grew 8%, with Shingrix contributing to adult immunization growth.

• Margin stabilization is expected to continue, with most low-hanging cost improvements already realized.

Product launches, pipeline, and regulatory updates

• New launches include Calpol extensions and upcoming oncology assets Zejula and Jemperli for gynecological cancers.

• Arexvy and other pipeline assets are undergoing clinical trials in India, with launches expected 18 months post-trial initiation.

• Bepirovirsen (hepatitis B) and MAPS (30-valent pneumococcal vaccine) are in clinical trials, with launches tied to global approvals and trial completion.

• Gepotidacin's commercial launch is under evaluation post-trial completion, based on market fit and pricing.

• No plans to launch HIV portfolio in India; licenses have been given to local companies.